Nurix Therapeutics, Inc.
NRIX · NASDAQ
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Market Cap | $786,048 | $891,671 | $1,291,014 | $1,733,660 |
| - Cash | $78,438 | $84,260 | $75,916 | $109,997 |
| + Debt | $56,486 | $51,931 | $26,623 | $28,303 |
| Enterprise Value | $764,096 | $859,342 | $1,241,721 | $1,651,966 |
| Revenue | $7,894 | $44,056 | $18,453 | $13,284 |
| % Growth | -82.1% | 138.7% | 38.9% | – |
| Gross Profit | $2,894 | -$34,040 | -$51,210 | -$53,940 |
| % Margin | 36.7% | -77.3% | -277.5% | -406.1% |
| EBITDA | -$81,421 | -$46,080 | -$60,514 | -$63,408 |
| % Margin | -1,031.4% | -104.6% | -327.9% | -477.3% |
| Net Income | -$86,421 | -$43,464 | -$56,351 | -$58,549 |
| % Margin | -1,094.8% | -98.7% | -305.4% | -440.7% |
| EPS Diluted | -1.03 | -0.52 | -0.67 | -0.75 |
| % Growth | -98.1% | 22.4% | 10.7% | – |
| Operating Cash Flow | -$57,385 | -$63,161 | -$61,087 | -$48,751 |
| Capital Expenditures | -$2,711 | -$2,675 | -$3,485 | -$2,105 |
| Free Cash Flow | -$60,096 | -$65,836 | -$64,572 | -$50,856 |